TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells
- PMID: 9469414
TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells
Abstract
Macrophages incubated with OVA in the presence of TGF-beta2 induce immune deviation in vivo (impaired delayed hypersensitivity and IgG2a Ab production) when injected into naive, syngeneic mice. OVA-specific TCR transgenic naive T cells (DO11.10 T cells) produce Th1-type cytokines when stimulated in vitro with OVA-pulsed peritoneal exudate cells (PEC), but if PEC are first treated with TGF-beta2 and then pulsed with OVA, the T cells secrete Th2-type cytokines instead. In this study, we investigated the mechanisms that are involved in the modified Ag-presenting functions of macrophages by TGF-beta2 pretreatment. We have found that: 1) TGF-beta2 impaired the capacity of PEC to produce IL-12 and to express CD40; 2) reduced CD40 expression on TGF-beta2-treated PEC impaired IL-12 production when the cells were cocultured with DO11.10 T cells; 3) the failure of TGF-beta2-treated PEC to stimulate DO11.10 T cells to secrete IFN-gamma was due to their impaired IL-12 production. From these results, we conclude that TGF-beta2 treatment impairs the ability of macrophages to produce IL-12 and to express CD40. As a consequence, TGF-beta2-treated PEC fail to promote development of pT cells toward the Th1 phenotype.
Similar articles
-
On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation.Eur J Immunol. 1997 Jul;27(7):1648-56. doi: 10.1002/eji.1830270709. Eur J Immunol. 1997. PMID: 9247573
-
Analysis of in vivo regulatory properties of T cells activated in vitro by TGFbeta2-treated antigen presenting cells.Invest Ophthalmol Vis Sci. 2000 May;41(6):1410-21. Invest Ophthalmol Vis Sci. 2000. PMID: 10798657
-
In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation.Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1803-11. Invest Ophthalmol Vis Sci. 2000. PMID: 10845601
-
Tolerogenic antigen-presenting cells: regulation of the immune response by TGF-beta-treated antigen-presenting cells.Immunol Res. 2004;30(2):155-70. doi: 10.1385/IR:30:2:155. Immunol Res. 2004. PMID: 15477657 Review.
-
Ocular immunosuppressive microenvironment.Chem Immunol. 1999;73:72-89. doi: 10.1159/000058738. Chem Immunol. 1999. PMID: 10590575 Review. No abstract available.
Cited by
-
Control of immune pathology by IL-10-secreting regulatory T cells.Springer Semin Immunopathol. 1999;21(3):287-94. doi: 10.1007/BF00812258. Springer Semin Immunopathol. 1999. PMID: 10666774 Review. No abstract available.
-
TGF-beta and CD23 are involved in nitric oxide production by pulmonary macrophages activated by beta-glucan from Paracoccidioides brasiliensis.Med Microbiol Immunol. 2010 Feb;199(1):61-9. doi: 10.1007/s00430-009-0138-1. Epub 2009 Dec 1. Med Microbiol Immunol. 2010. PMID: 19949959
-
Pharmacotherapy for uveitis: current management and emerging therapy.Clin Ophthalmol. 2014 Sep 22;8:1891-911. doi: 10.2147/OPTH.S47778. eCollection 2014. Clin Ophthalmol. 2014. PMID: 25284976 Free PMC article. Review.
-
Serum and urine interleukin-6 and transforming growth factor-beta1 in young infants with pyelonephritis.Int Urol Nephrol. 2007;39(2):581-5. doi: 10.1007/s11255-006-9045-1. Epub 2007 Feb 21. Int Urol Nephrol. 2007. PMID: 17318354
-
CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination.J Immunol. 2010 Dec 1;185(11):6706-18. doi: 10.4049/jimmunol.0903411. Epub 2010 Nov 1. J Immunol. 2010. PMID: 21041723 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials